Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban Versus Low-molecular-weight Heparin in Preventing Thrombosis Among Cancer Patients After Femoral Venepuncture

NCT03282643 is registered in ClinicalTrials.gov with Capital Medical University as lead sponsor.

NCT NCT03282643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03282643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban Versus Low-molecular-weight Heparin in Preventing Thrombosis Among Cancer Patients After Femoral Venepuncture
Lead sponsor
Capital Medical University
Phase
Phase 1/2
Overall status
Completed
Start date
February 16, 2016
Completion date
April 1, 2019
Enrollment
74 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms